|
November 21, 2022
|
Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma
|
|
|
November 8, 2022
|
Caribou Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update
|
|
|
November 7, 2022
|
Caribou Biosciences to Participate in Upcoming Investor Conferences
|
|
|
November 3, 2022
|
Caribou Biosciences to Present ANTLER Trial-in-Progress Poster at the 64th American Society of Hematology Annual Meeting
|
|
|
October 18, 2022
|
Caribou Biosciences Presents Case Report on Long-term Follow up of First Patient Dosed in Phase 1 ANTLER Trial at the Lymphoma, Leukemia, & Myeloma Congress 2022
|
|
|
August 31, 2022
|
Caribou Biosciences to Participate in Upcoming Investor Conferences
|
|
|
August 9, 2022
|
Caribou Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
|
|
|
June 10, 2022
|
Caribou Biosciences Reports Positive Additional Data from CB-010 Allogeneic CAR-T Cell Therapy Phase 1 ANTLER Trial at the European Hematology Association (EHA) 2022 Hybrid Congress
|
|
|
June 1, 2022
|
Caribou Biosciences Announces Webcast Conference Call to Highlight Initial CB-010 ANTLER Phase 1 Data Presentation at EHA on June 10, 2022
|
|
|
May 16, 2022
|
Caribou Biosciences Presents Data on Mechanism Underlying Superior Specificity of Caribou’s chRDNA Genome-Editing Technology in Primary Human T cells
|
|
